araag2/HINT huggingface dataset:
Clinical trial NCT00617994 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ruxolitinib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have psoriatic lesions measuring protocol specific BSA

        Exclusion Criteria:

          -  Lesions solely involving the palms of the hands, the soles of the feet, the
             intertriginious areas, the scalp or the face

          -  Pustular psoriasis or erythroderma
Clinical trial NCT00079482 (phase 2, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: cep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)
SMILES: C[C@]12O[C@H](C[C@]1(O)CO)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C3C(=O)NC4)C3=CC=CC=C3N21, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion criteria:

          -  cytological confirmation of AML;

          -  relapsed disease following first CR of 1 month(30days)to 24 months(730days). The time
             from first relapse to study entry (start of first course of induction chemotherapy)
             must be no longer than 30days;

          -  confirmation of FLT-3 activating mutation positive status after point of initial
             relapse;

          -  aged 18 years or older;

          -  written informed consent;

          -  ability to understand and comply with study restrictions;

          -  no comorbid conditions that would limit life expectancy to less than 3 months;

          -  ECOG Performance Score of 0, 1,or 2;

          -  women must be neither pregnant nor lactating, and either of non-childbearing potential
             or using adequate contraception with a negative pregnancy test at study entry

        Exclusion criteria:

          -  bilirubin > 2x ULN;

          -  ALT/AST > 3x ULN;

          -  serum creatinine > 1.5 mg/dL;

          -  resting ejection fraction of left ventricle l < 45%(applies only to patients scheduled
             to receive mitoxantrone, etoposide, and cytarabine [MEC];

          -  untreated or progressive infection;

          -  any physical or psychiatric cdtn that may compromise participation in the study;

          -  known CNS involvement with AML;

          -  any previous treatment with a FLT-3 inhibitor;

          -  requires current treatment for HIV with protease inhibitors;

          -  active GI ulceration or bleeding;

          -  use of an investigational drug that is not expected to be cleared by the start of
             CEP-701 treatment
Clinical trial NCT00472420 (phase 2, status: completed)
Conditions: mantle cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab [mabthera/rituxan], first line chemotherapy
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  histologically-proven mantle cell lymphoma;

          -  previously untreated disease at stage II, III and IV, requiring therapy.

        Exclusion Criteria:

          -  known hypersensitivity reaction to rituximab, or known anti-murine antibody reactivity
             or known hypersensitivity to murine antibodies;

          -  active malignancy other than mantle cell lymphoma within 5 years of start of study,
             with the exception of resected basal cell cancer, squamous cell cancer of the skin, or
             in situ cancer of the cervix;

          -  serious disorders interfering with full standard dosing chemotherapy;

          -  stage I disease.
Clinical trial NCT00465673 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: liposomal doxorubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proved breast cancer

          -  Relapse/recurrent brain metastasis progression after brain radiotherapy

          -  Presence of brain measurable disease which is defined as at least one brain lesion
             that can be measured in at least 1 dimension as ³ 20 mm with magnetic resonance image
             (MRI)

          -  Prior chemotherapy or hormone therapy for metastatic breast cancer is allowed

          -  Performance status of ECOG 0, 1, 2

          -  With normal left ventricular ejection fraction and normal ventricular contractility

          -  Age 21 years or older

          -  Life expectancy equal or longer than 3 months

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior anthracycline-containing chemotherapy with cumulative dose exceed 400mg/m2
             doxorubicin or 750 mg/m2 Epirubicin

          -  Surgery , radiotherapy, hormonal therapy or chemotherapy within 4 weeks prior to
             entering the study

          -  Prior liposomal doxorubicin treatment

          -  Concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug
             except non-disease related conditions (e.g. insulin for diabetes) during study period

          -  Other malignancy with exception of curative treated non-melanoma skin cancer or
             cervical carcinoma in situ within 5 years prior to entering the study

          -  Brain metastases defined as meninges metastases

          -  Presence of serious concomitant illness which might be aggravated by study medication:

               -  Uncontrolled infection (active serious infections that are not controlled by
                  antibiotics)

               -  Active cardiac disease e.g. decompensate myocardial infarction within the 6-month
                  period preceding entry into the study.

               -  History of ventricular arrhythmia or congestive heart failure.

          -  Presence of abnormal left ventricular ejection fraction

          -  Hematopoietic function as defined below:

               -  Hemoglobin<10g/dl

               -  ANC< 1,500/uL

               -  Platelets<100,000/uL

          -  Organ function as defined below:

               -  Total bilirubin >1.5 × ULN

               -  ALT / AST>3 × ULN (>5.0 x ULN if hepatic metastasis)

               -  Creatinine >1.5 × ULN

          -  Mental status is not fit for clinical trial

          -  Pregnant or breast feeding women, or women of child-bearing potential unless using a
             reliable and appropriate contraceptive method
Clinical trial NCT01510990 (phase 2, status: unknown status)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion criteria

          -  More than 18 years of age

          -  Advanced or metastatic adenocarcinoma of the lung. Non-smoking or light smoking
             patients (less than 10 PY smoking and more than 10 years of ex-smoking period) are
             preferred to enrich the patients with clinical response to gefitinib.

          -  Chemonaive patients.

          -  At least one lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short
             axis ≥ 15 mm) with computed tomography (CT) or and which is suitable for accurate
             repeated measurements.

          -  ECOG PS 0-2

          -  Patients with tissue for the detection of EGFR mutation

          -  At least 1 week since the last radiotherapy. Patients must have recovered from all
             acute toxicities from radiotherapy.

          -  Patients must have adequate hematologic, renal and liver function as defined by Hb >
             9g/dL, neutrophils > 1000/mm3, platelets > 50,000/mm3, creatinine < 2mg/dL, and AST
             (SGOT) and/or ALT (SGPT) < 5 x UNL (upper normal limit).

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests and other study procedures.

          -  Written and voluntary informed consent understood, signed and dated.

        Exclusion criteria

          -  Symptomatic brain metastasis. Brain metastases stable < 2 weeks before dosing or
             requiring concurrent steroid treatment or with clinical symptoms.

          -  Major surgery within 3 weeks prior to study enrollment.

          -  Previous (less than 3 years ago) or current malignancies at sites other than
             curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of
             the skin.

          -  Past medical history of interstitial lung diseas, drug induced interstitial disease,
             radiation pneumonitis which required steroid treatment or any active interstitial lung
             disease.

          -  Pre-existing idiopathic pulmonary fibrosis on CT scans on baseline.

          -  Insufficient lung function as determined by either clinical examination or an arterial
             oxygen tension (PaO2) < 70mmHg.

          -  Uncontrolled diabetes mellitus and FBS > 150mg/dL.

          -  Severe medical illness or active infection that would impair the ability to receive
             gefitinib.

          -  Pregnancy or breast feeding.
Clinical trial NCT00423280 (phase 2, status: unknown status)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: 6r-bh4
SMILES: [H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Multi-vessel coronary artery disease scheduled for coronary artery bypass surgery
             (CABG)

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Female subject who is pregnant, lactating or planning pregnancy during course of study

          -  Prior clinical diagnosis of heart failure requiring diuretic therapy with evidence of
             severe left ventricular dysfunction

          -  Recent acute coronary event (<4 weeks)

          -  Emergency CABG

          -  Newly diagnosed diabetes mellitus (<1 month)

          -  Body weight >130kg

          -  Impaired renal function (creatinine >180umol/l)

          -  Elevated liver function tests (ALT >50umol/l or AST >2x normal)

          -  Pacemakers, ICDs or metallic implants not compatible with MRI scanning

          -  Subjects receiving experimental medications or participating in another study

          -  Terminally ill subjects

          -  Known hypersensitivity to 6R-BH4

          -  Concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors
Clinical trial NCT00494234 (phase 2, status: active, not recruiting)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ku-0059436 (azd2281) (parp inhibitor), ku-0059436 (azd2281) (parp inhibitor)
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced breast cancer with positive BRCA1 or BRCA2 status

          -  Failed at least one prior chemotherapy

          -  In investigators opinion, no curative standard therapy exists

          -  Measurable disease

        Exclusion Criteria:

          -  Brain metastases

          -  Less than 28 days since last treatment used to treat the disease

          -  Considered a poor medical risk due to a serious uncontrolled disorder
Clinical trial NCT00039741 (phase 2/phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: nrtis (abc, ftc, ftc/tdf, 3tc, 3tc/azt, d4t, tdf, ddc, azt), nnrtis (efv, nvp), pis (amp, idv, lpv/r, nfv, sqv, rtv)
SMILES: CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O, CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Older than 30 days and younger than 18 years of age (may enroll up to the day before
             their 18th birthday)

          -  HIV infected

          -  Not previously on HAART or received anti-HIV drugs for less than 56 consecutive days
             after birth to prevent mother-to-infant HIV transmission. Participants who have
             previously received nevirapine for the prevention of mother-to-infant HIV transmission
             are not eligible for this study.

          -  Willing to use acceptable methods of contraception

        Exclusion Criteria:

          -  Grade 3 or 4 clinical or laboratory toxicity. More information on this criterion can
             be found in the protocol.

          -  Active opportunistic infection or a serious bacterial infection at the time of study
             entry

          -  Pancreas, nervous system, blood, liver, or kidney problems that make it impossible to
             take study medications

          -  Taking any medication that cannot be combined with the study medications in first-line
             therapy

          -  Received therapy for cancer

          -  Pregnant or breastfeeding
Clinical trial NCT01333449 (phase 2, status: terminated)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Reason stopped: 
    poor subject accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Newly diagnosed MDS patients aged 21 to 65 years belonging to any of the following
             categories: refractory cytopenia with multilineage dysplasia (RCMD) with or without
             ringed sideroblasts (i.e. RCMD and RCMD-RS), refractory anemia with excess blasts-1
             (RAEB-1) or RAEB-2 if the prognostic scores are IPSS (international prognostic scoring
             system) Int-2 or IPSS-high or with WPSS (WHO prognostic scoring system) 3 and above

          2. Therapy-related MDS with IPSS Int-2 and above or WPSS 3

          3. Acceptable cardiac function MUGA or Echocardiography left ventricular ejection
             fraction of 40% and above

          4. Acceptable lung function: FEV1>70% predicted, DLCO>60% predicted

          5. Acceptable renal function: CCT > 50ml/min

          6. Acceptable liver function: abnormalities in bilirubin or transaminases not > 2times
             upper limit of normal

          7. Performance status of ECOG 2 or HCT-specific Comorbidity Index < 3

        Exclusion Criteria:

          1. Any co-morbidity other than MDS which limits life-expectancy to <3mth

          2. Diagnosis of other active cancer other than squamous cell carcinoma, basal cell
             carcinoma or carcinoma-in-situ 1 or 2 of the cervix

          3. Presence of active infections not under control

          4. Receipt of 5-azacytidine or other induction chemotherapy for MDS/AML

          5. Patients not keen to explore allogeneic HCT as part of curative treatment plan

          6. Pregnancy
Clinical trial NCT00376935 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: palifermin, palifermin placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infected

          -  Receiving potent ART, defined as a combination of three or more antiretroviral drugs
             for at least 6 months prior to study entry

          -  CD4 count of 200 cells/mm3 or less within 30 days prior to study entry

          -  Documented CD4 count obtained at study screening

          -  Documented current, persistent viral load less than or equal to 200 copies/ml for at
             least 6 months prior to study entry

          -  Willing to use acceptable forms of contraception for the duration of the study

        Exclusion Criteria:

          -  Active pancreatitis

          -  Androgens, Immunomodulators (e.g., growth factors, systemic corticosteroids, HIV
             vaccines, immune globulin, interleukins, interferons), or investigational ART within
             30 days prior to study entry

          -  Systemic cancer chemotherapy within 30 days prior to study entry, or history of
             radiation therapy to the neck and chest regions at any time.

          -  Allergy or sensitivity to any component of palifermin

          -  Prior treatment with palifermin or other keratinocyte growth factors

          -  Current drug or alcohol use that, in the opinion of the investigator, may interfere
             with study participation

          -  Serious illness or recent surgery that requires systemic treatment or hospitalization.
             Participants who have completed therapy or are clinically stable on therapy for at
             least 30 days prior to study entry are not excluded.

          -  Active cancer

          -  HIV-1 RNA levels >200 copies/mL within 6 months prior to study entry

          -  Pregnant or breastfeeding
Clinical trial NCT00265551 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: sca-136 (200 mg), sca-136 (400 mg), olanzapine (15 mg), placebo
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia

          -  Ability to remain hospitalized for at least first 4 weeks of study

          -  Needs hospitalization due to worsening of schizophrenia

        Exclusion Criteria:

          -  Type 1 or 2 diabetes

          -  Previous use of clozapine

          -  Serious medical illness other than schizophrenia
Clinical trial NCT00258362 (phase 2, status: completed)
Conditions: endometrial cancer
ICD codes: N85.00, N85.01, N85.02, N99.85
Drugs: carboplatin, docetaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed endometrial cancer

          -  Advanced or recurrent disease

               -  Stage IIIB or IIIC disease

                    -  Stage IIIA disease allowed provided there is serosal involvement or direct
                       extension or metastasis to the adnexa

                    -  No stage IIIA confirmed by only positive peritoneal washings

               -  Stage IVA or IVB disease

          -  Failed local therapy or considered incurable with local therapy

          -  Measurable or evaluable disease

               -  Not required for newly diagnosed stage III or IV disease with no remaining
                  disease after surgery

          -  Performance status Gynecology Oncology Group (GOG) 0-1

          -  Life expectancy at least 12 weeks

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL

          -  Meets 1 of the following criteria:

               -  Alkaline phosphatase (AP) normal AND aspartate aminotransferase (AST) or alanine
                  aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN)

               -  AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN

               -  AP ≤ 5 times ULN AND AST or ALT normal

          -  Bilirubin normal

          -  No acute hepatitis

          -  Creatinine ≤ 1.5 mg/dL

        Exclusion Criteria:

          -  Known hypersensitivity to docetaxel or polysorbate 80

          -  Severe infection

          -  Septicemia

          -  Pregnant or nursing

          -  Positive pregnancy test

          -  Fertile patients must use effective nonhormonal contraception during and for at least
             3 months after study treatment

          -  Peripheral neuropathy ≥ grade 2

          -  Severe gastrointestinal bleeding requiring a blood transfusion or hospitalization

          -  Other malignancy within the past 5 years except nonmetastatic, nonmelanoma skin cancer
             or carcinoma in situ of the cervix

          -  Prior chemotherapy

          -  Prior radiotherapy
Clinical trial NCT01391013 (phase 2, status: completed)
Conditions: human immunodeficiency virus 1
ICD codes: D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: darunavir(drv), ritonavir, 2 nucleoside reverse transcriptase inhibitors (nrtis)
SMILES: [H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Inclusion Criteria: - Human immunodeficiency virus-1 (HIV-1) infected participants on their
        first-line treatment with highly active antiretroviral therapy (HAART) (combination of 2 or
        3 nucleoside reverse transcriptase inhibitors [NRTIs] with at least 1 additional
        antiretroviral [ARV] from the non-nucleoside reverse transcriptase inhibitor [NNRTI] and/or
        protease inhibitors [PI] class) for at least 24 weeks, provided the same ARV combination
        for at least 8 weeks before screening

          -  Participants' preference for a more convenient regimen and/or any current or history
             of toxicity on actual regimen

          -  Plasma HIV-1 ribonucleic acid (RNA) less than 50 cp/ml for at least 24 weeks before
             screening, where single viral blips of more than 50 copies/mL are allowed

          -  Cluster of differentiation 4 (CD4) count more than 100/mm3 at the start of HAART and
             more than 200/mm3 at screening

          -  Healthy on the basis of physical examination, medical history, vital signs, clinical
             laboratory tests, and 12-lead electrocardiogram performed at screening

          -  Agrees to protocol-defined use of effective contraception

          -  Postmenopausal, surgically sterile, or abstinent female participants

        Exclusion Criteria:

          -  History of coronary heart disease, uncontrolled hypertension, peripheral vascular
             disease and or cerebrovascular disease

          -  History of virological failure on highly active antiretroviral therapy, plasma HIV-1
             ribonucleic acid more than 500 copies/mL after initial full virological suppression
             while on ARV therapy and any PI mutations

          -  Participants with significantly hepatic and liver insufficiency or diagnosed with
             acute viral hepatitis or have active clinically significant diseases and acquired
             immune deficiency syndrome (AIDS) defining illness at screening

          -  Current significant tobacco use, active drug or alcohol use or dependence

          -  Use of lipid-lowering drugs within 4 weeks prior to study entry and use of
             testosterone, anabolic steroids, oral contraceptives or hormonal replacement within 12
             weeks prior to study entry or previous or current use of darunavir

          -  Use of systemic glucocorticoids, long-acting inhaled steroids (inhaled via mouth or
             nose), or other immunomodulators within 30 days prior to study entry